Online inquiry

IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6085MR)

This product GTTS-WQ6085MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6085MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7911MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ14939MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ6847MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ12993MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ11333MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ12767MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ15789MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ7768MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW